ATX inhibitors

Oncology

Tackling the fibroblast cells that form scar tissue around tumours takes down a barrier that prevents or inhibits the effect of many therapies.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.